These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 16130613

  • 1. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN, Ranjan A, Bimal S, Siddique NA, Pandey K, Kumar N, Verma N, Singh VP, Sinha PK, Bhattacharya SK.
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [Abstract] [Full Text] [Related]

  • 2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S.
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [Abstract] [Full Text] [Related]

  • 3. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
    Giri OP, Singh AN.
    J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
    [Abstract] [Full Text] [Related]

  • 4. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB, Yang CM, Zhang CJ.
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract] [Full Text] [Related]

  • 5. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
    Verma SK, Ahmad S, Shirazi N, Kusum A, Kaushik RM, Barthwal SP.
    Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
    [Abstract] [Full Text] [Related]

  • 6. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP, Thakur S, Narayan S, Sinha A.
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [Abstract] [Full Text] [Related]

  • 7. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 8. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.
    Clin Infect Dis; 2008 Oct 15; 47(8):1000-6. PubMed ID: 18781879
    [Abstract] [Full Text] [Related]

  • 9. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
    Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D.
    J Infect Dis; 1999 Aug 15; 180(2):564-7. PubMed ID: 10395884
    [Abstract] [Full Text] [Related]

  • 10. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
    Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R.
    J Antimicrob Chemother; 2006 Oct 15; 58(4):811-5. PubMed ID: 16916865
    [Abstract] [Full Text] [Related]

  • 11. Amphotericin B in resistant kala-azar in Bihar.
    Thakur CP, Sinha GP, Pandey AK, Barat D, Sinha PK.
    Natl Med J India; 1993 Oct 15; 6(2):57-60. PubMed ID: 8477209
    [Abstract] [Full Text] [Related]

  • 12. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
    Sharief AH, Gasim Khalil EA, Theander TG, Kharazmi A, Omer SA, Ibrahim ME.
    Exp Parasitol; 2006 Dec 15; 114(4):247-52. PubMed ID: 16716301
    [Abstract] [Full Text] [Related]

  • 13. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
    Escobar P, Yardley V, Croft SL.
    Antimicrob Agents Chemother; 2001 Jun 15; 45(6):1872-5. PubMed ID: 11353640
    [Abstract] [Full Text] [Related]

  • 14. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.
    N Engl J Med; 2007 Jun 21; 356(25):2571-81. PubMed ID: 17582067
    [Abstract] [Full Text] [Related]

  • 15. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN.
    Bull World Health Organ; 2001 Jun 21; 79(5):388-93. PubMed ID: 11417033
    [Abstract] [Full Text] [Related]

  • 16. Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.
    Thakur CP, Dedet JP, Narain S, Pratlong F.
    Trans R Soc Trop Med Hyg; 2001 Jun 21; 95(2):187-9. PubMed ID: 11355558
    [Abstract] [Full Text] [Related]

  • 17. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP, Narayan S, Ranjan A.
    Indian J Med Res; 2004 Sep 21; 120(3):166-72. PubMed ID: 15489554
    [Abstract] [Full Text] [Related]

  • 18. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J.
    N Engl J Med; 2002 Nov 28; 347(22):1739-46. PubMed ID: 12456849
    [Abstract] [Full Text] [Related]

  • 19. Studies on stibanate resistant Leishmania donovani isolates of Indian origin.
    Pal S, Mandal A, Duttagupta S.
    Indian J Exp Biol; 2001 Mar 28; 39(3):249-54. PubMed ID: 11495284
    [Abstract] [Full Text] [Related]

  • 20. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A, Seth A, Kaur S, Aneja S, Rath B, Basu S, Patel R, Dutta AK.
    Pediatr Infect Dis J; 2011 Feb 28; 30(2):180-1. PubMed ID: 20823781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.